Please login to the form below

Not currently logged in
Email:
Password:

Pan

This page shows the latest Pan news and features for those working in and with pharma, biotech and healthcare.

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

Whilst Keytruda was the first therapy to be approved for pan-tumour use in 2017, its Microsatellite Instability-High or Mismatch Repair-Deficient indication differs from the NTRK TA therapies.

Latest news

More from news
Approximately 6 fully matching, plus 229 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest appointments

More from appointments
Approximately 11 fully matching, plus 32 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 31 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....